[Bone marrow transplantation in chronic myeloid leukemia].
Bone marrow transplantation (BMT) is at present the only curative therapy for chronic myelogenous leukemia (CML). The outcome of this therapy is much better if marrow transplantation from HLA-matched siblings is performed within 1 year of diagnosis, in young patients and in the chronic phase of the disease. BMT from HLA-matched unrelated donors expands the application of this therapy among CML patients with no available identical siblings. Autologous bone marrow transplantation is presently considered in patients unresponsive to interferon therapy or with high risk of blastic transformation.
Hansz
J
J
Kliniki Hematologii AM, Poznaniu.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods*; D002648:Child; D006086:Graft vs Host Disease / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D012307:Risk Factors; D014019:Tissue Donors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
D006680:HLA Antigens
Przeszczepianie szpiku kostnego w przewlekłej białaczce szpikowej.